Cargando…

Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old

This study aimed to analyze the survival rate and to examine the risk of death from prostate cancer when accounting for competing risk of death, in men aged ≥80 y treated with primary androgen deprivation therapy (ADT). Data of patients with prostate cancer who had received ADT were extracted from a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blas, Leandro, Onozawa, Mizuki, Shiota, Masaki, Hinotsu, Shiro, Sakamoto, Shinichi, Kitagawa, Yasuhide, Kawai, Taketo, Eto, Masatoshi, Kume, Haruki, Akaza, Hideyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353900/ https://www.ncbi.nlm.nih.gov/pubmed/34014592 http://dx.doi.org/10.1111/cas.14974

Ejemplares similares

A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy
por: Taguchi, Satoru, et al.
Publicado: (2023)

Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-1)
por: Ueno, Satoru, et al.
Publicado: (2018)

Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community‐based multi‐institutional database across Japan using propensity score matching
por: Onozawa, Mizuki, et al.
Publicado: (2018)

Modified J‐CAPRA scoring system in predicting treatment outcomes of metastatic prostate cancer patients undergoing androgen deprivation therapy
por: Lim, Jasmine, et al.
Publicado: (2020)

Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: Comparing between high‐ and middle‐income Asian countries
por: Lim, Jasmine, et al.
Publicado: (2021)

Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score
por: Akaza, Hideyuki, et al.
Publicado: (2013)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)

Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy
por: Shiota, Masaki, et al.
Publicado: (2022)

Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data
por: Blas, Leandro, et al.
Publicado: (2022)

Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer
por: Hirata, Yu, et al.
Publicado: (2019)

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy
por: Shiota, Masaki, et al.
Publicado: (2018)

Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
por: Kashiwagi, Eiji, et al.
Publicado: (2020)

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
por: Akitake, Naoko, et al.
Publicado: (2018)

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective
por: Matsumoto, Takashi, et al.
Publicado: (2022)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
por: Yamada, Shigetomo, et al.
Publicado: (2022)

Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Genetic variations predicting progression with docetaxel and novel androgen‐receptor pathway inhibitors
por: Shiota, Masaki, et al.
Publicado: (2023)

Asian trends in primary androgen depletion therapy on prostate cancer
por: Akaza, Hideyuki
Publicado: (2013)

Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone
por: Shiota, Masaki, et al.
Publicado: (2019)

Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors
por: Matsumoto, Takashi, et al.
Publicado: (2021)

Detection and Cloning of a Protein Recognized by Anti‐human Prostate‐specific Antigen (PSA) Antibody in the Rat Ventral Prostate
por: Onozawa, Mizuki, et al.
Publicado: (2001)

Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence
por: Izumi, Koji, et al.
Publicado: (2016)

Androgen deprivation therapy prevents bladder cancer recurrence
por: Izumi, Koji, et al.
Publicado: (2014)

Regional difference in cancer detection rate in prostate cancer screening by a local municipality in Japan
por: Koizumi, Chie, et al.
Publicado: (2014)

Radiotherapy plus androgen deprivation therapy for prostate‐specific antigen persistence in lymph node–positive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2022)

Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management
por: Akaza, Hideyuki, et al.
Publicado: (2014)

Report of the third Asian Prostate Cancer study meeting
por: Lojanapiwat, Bannakij, et al.
Publicado: (2019)

Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer
por: Sato, Yuzuri Tsurumaki, et al.
Publicado: (2014)

A rare case of de novo large cell neuroendocrine carcinoma of the prostate with long-term survival after cystoprostatectomy and androgen deprivation
por: Miyakawa, Jimpei, et al.
Publicado: (2018)

External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy
por: Blas, Leandro, et al.
Publicado: (2022)

Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial
por: Oyama, Masafumi, et al.
Publicado: (2017)

Adenoma-carcinoma Sequence in the Bladder After Augmentation Cystoplasty
por: Naito, Akihiro, et al.
Publicado: (2014)

Effects of a Soybean Isoflavone Mixture on Carcinogenesis in Prostate and Seminal Vesicles of F344 Rats
por: Onozawa, Mizuki, et al.
Publicado: (1999)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Validation of user-friendly models predicting extracapsular extension in prostate cancer patients
por: Blas, Leandro, et al.
Publicado: (2023)

Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer
por: Taguchi, Satoru, et al.
Publicado: (2014)

The prognostic value of PD‐L1 expression in upper tract urothelial carcinoma varies according to platelet count
por: Miyama, Yu, et al.
Publicado: (2018)

Nose size indicates maximum penile length
por: Ikegaya, Hiroshi, et al.
Publicado: (2021)

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
por: Chikamatsu, Sotaro, et al.
Publicado: (2022)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_unj80a1u1hs9tthlcmgdlrbrvo